Abstract
Platelet inhibitors and anticoagulants are called antithrombotic drugs. New platelet inhibitors prasugrel and ticagrelor are more effective than the traditional clopidogrel, but their use is also accompanied by more frequent bleeding complications. Varfarin has gained true competitors; new oral anticoagulants include dabigatran, rivaroxaban and apixaban. New anticoagulants are easier to use but clearly more expensive. The use of new anticoagulants is also accompanied by several potential problems that the clinician should be aware of.
MeSH terms
-
Adenosine / analogs & derivatives
-
Adenosine / therapeutic use
-
Anticoagulants / therapeutic use*
-
Benzimidazoles / therapeutic use
-
Clopidogrel
-
Dabigatran
-
Hemorrhage / chemically induced
-
Humans
-
Morpholines / therapeutic use
-
Piperazines / therapeutic use
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prasugrel Hydrochloride
-
Pyrazoles / therapeutic use
-
Pyridones / therapeutic use
-
Rivaroxaban
-
Thiophenes / therapeutic use
-
Ticagrelor
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Warfarin / therapeutic use
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / therapeutic use
Substances
-
Anticoagulants
-
Benzimidazoles
-
Morpholines
-
Piperazines
-
Platelet Aggregation Inhibitors
-
Pyrazoles
-
Pyridones
-
Thiophenes
-
beta-Alanine
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Clopidogrel
-
Prasugrel Hydrochloride
-
Ticagrelor
-
Dabigatran
-
Adenosine
-
Ticlopidine